Receive our newsletter – data, insights and analysis delivered to you
June 4, 2009

Wyeth’s Enbrel Gets European Thumbs Up

Wyeth has received positive recommendations from the European Committee for Medicinal Products for Human Use (CHMP) for Enbrel (etanercept). The recommendations were awarded for two versions of the tumour necrosis factor alpha inhibitor treatment used for plaque psoriasis, rheumatoid arth

By cms admin

Wyeth has received positive recommendations from the European Committee for Medicinal Products for Human Use (CHMP) for Enbrel (etanercept).

The recommendations were awarded for two versions of the tumour necrosis factor alpha inhibitor treatment used for plaque psoriasis, rheumatoid arthritis and other related inflammatory conditions.

Enbrel is currently approved for intermittent treatment of adult plaque psoriasis.

Wyeth Europa assistant vice president, immunology Michael Zaiac said that this is a significant step towards improving the management of what can be a disabling and potentially stigmatising condition.

β€œIt is hoped that the sustained efficacy achieved with Enbrel in the continuous and intermittent dosing options will allow for greater individualised approach to psoriasis patient care,” said Zaiac.

CHMP provided its positive recommendation of a continuous dosing regimen for Enbrel based on data from the Crystel trial.

The Crystel trial examined the efficacy and safety of Enbrel using continuous or intermittent dosing regimens for up to 54 weeks.

Results from the Crystel study demonstrated that patients in the continuous and intermittent treatment groups experienced significant improvement in their conditions from baseline.

Both groups were highly satisfied with the result of their treatment. There were no new safety signals in either the continuous or intermittent treatment groups.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU